Dioh, W.
Chabane, M.
Tourette, C.
Azbekyan, A.
Morelot-Panzini, C.
Hajjar, L. A.
Lins, M.
Nair, G. B.
Whitehouse, T.
Mariani, J.
Latil, M.
Camelo, S.
Lafont, R.
Dilda, P. J.
Veillet, S.
Agus, S.
Article History
Received: 17 December 2020
Accepted: 23 December 2020
First Online: 11 January 2021
Ethics approval and consent to participate
: The current clinical protocol version 10 was approved by the French and Belgium ethic committees. The submission to EC in Brazil, UK and US is ongoing.Belgium: Ethics committee Universitair Ziekenhuis Antwerpen Ethisch Comité Ethical approval number: 2020-001498-63/SM003. Date of approval: October, 2<sup>nd</sup>, 2020.France Ethics committee Le Comité de Protection des Personnes (CPP) Ouest V Ethical approval number: 20/028-1 COVID (CNRIPH ref: 20.04.01.63336), date of approval: December, 1<sup>st</sup> , 2020.We certify that this trial has received approvals from the appropriate ethical committees as described above. Written informed consent will be obtained from the patient or legal authorized representative.
: Not applicable.
: We declare non-competing interest that all authors apart from CMP, LAH, ML, TW and GBN are employees of BIOPHYTIS SA. We believe, however, that the company’s potential commercial interests had no impact on the scientific rationale or conduct of the trial.CMP, LAH, ML, TW and GBN are members of the COVA steering committee and country clinical investigators and declare no-competing interests.